NCT06941961 iTBS for Acute Ischemic Stroke After Thrombectomy
| NCT ID | NCT06941961 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yi Yang |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 178 participants |
| Start Date | 2025-04-25 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 178 participants in total. It began in 2025-04-25 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.
Eligibility Criteria
Inclusion Criteria: * 1\) Age 18-85 years, regardless of gender. * 2\) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA. * 3\) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset. * 4\) Successful Reperfusion: Post-MT eTICI score ≥ 2b. * 5\) NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb. Exclusion Criteria: * 1\) Pre-stroke modified Rankin Scale (mRS) score ≥2. * 2\) PH2-type intracranial hemorrhage on brain CT post-MT. * 3\) Patients who underwent intracranial stent placement during MT. * 4\) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic/magnetic-sensitive devices. * 5\) Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS. * 6\) Expected survival \<3 months due to other medical conditions or inability to complete follow-up for any reason. * 7\) Participation in another interventional study. * 8\) Any other condition deemed unsuitable for enrollment by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06941961 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06941961 currently recruiting?
Yes, NCT06941961 is actively recruiting participants. Contact the research team at doctor_yangyi@163.com for enrollment information.
Where is the NCT06941961 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT06941961 clinical trial?
NCT06941961 is sponsored by Yi Yang. The trial plans to enroll 178 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.